IBI311 clinical trials
Also written IBI311.
How each study uses IBI311 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IBI311 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI311
- 8
Studies by the year they started
9 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 4
Innovent Biologics (Suzhou) Co. Ltd. (5) · Shanghai Changzheng Hospital (3) · Peking University People's Hospital (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test IBI311, phase 3 first.
- Dec 2026A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseasePhase 3 · Innovent Biologics (Suzhou) Co. Ltd.
- Apr 2027The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.Phase 4 · Shanghai Changzheng Hospital
- May 2027Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.Phase 4 · Shanghai Changzheng Hospital
- Jul 2027Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAOPhase 4 · Shanghai Changzheng Hospital
Studies
Open first, then newest update. How each study uses IBI311 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye DiseaseRecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07113262Written as IBI311
- Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment.RecruitingPhase 4Shanghai Changzheng HospitalNCT07152366Written as IBI311
- The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment.RecruitingPhase 4Shanghai Changzheng HospitalNCT07152340Written as IBI311
- Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAORecruitingPhase 4Shanghai Changzheng HospitalNCT07152392Written as IBI311
- A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye DiseaseCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT06126783Written as IBI311
- A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated OphthalmopathyCompletedPhase 3Peking University People's HospitalNCT06269393Written as IBI311
- A Study of IBI311 in Subjects With Inactive or Active Thyroid Eye DiseaseCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT06525506Written as IBI311 (20 mg)
- A Study of IBI311 in Subjects With Active Thyroid Eye DiseaseCompletedPhase 2/3Innovent Biologics (Suzhou) Co. Ltd.NCT05795621Written as IBI311
- A Study of IBI311 in Healthy VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05480579Written as IBI311